TXMD Valuation

TherapeuticsMD Inc

Add to Watchlist

Advanced Chart

1.105

+0.045(4.245%)1D

Overview
Forecast
Valuation
Earnings

TXMD Relative Valuation

TXMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TXMD is overvalued; if below, it's undervalued.

Historical Valuation

TherapeuticsMD Inc (TXMD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.40 is considered Undervalued compared with the five-year average of -0.80. The fair price of TherapeuticsMD Inc (TXMD) is between 2.34 to 2.74 according to relative valuation methord. Compared to the current price of 1.05 USD , TherapeuticsMD Inc is Undervalued By 55.07%.

Relative Value

Fair Zone

2.34-2.74

Current Price：1.05

55.07%

Undervalued

6.63

Trailing

Forward

0.10

EV/EBITDA

TherapeuticsMD Inc. (TXMD) has a current EV/EBITDA of 0.10. The 5-year average EV/EBITDA is -1.65. The thresholds are as follows: Strongly Undervalued below -8.70, Undervalued between -8.70 and -5.18, Fairly Valued between 1.87 and -5.18, Overvalued between 1.87 and 5.39, and Strongly Overvalued above 5.39. The current Forward EV/EBITDA of 0.10 falls within the Historic Trend Line -Fairly Valued range.

5.82

EV/EBIT

TherapeuticsMD Inc. (TXMD) has a current EV/EBIT of 5.82. The 5-year average EV/EBIT is -3.42. The thresholds are as follows: Strongly Undervalued below -26.42, Undervalued between -26.42 and -14.92, Fairly Valued between 8.08 and -14.92, Overvalued between 8.08 and 19.58, and Strongly Overvalued above 19.58. The current Forward EV/EBIT of 5.82 falls within the Historic Trend Line -Fairly Valued range.

1.40

TherapeuticsMD Inc. (TXMD) has a current PS of 1.40. The 5-year average PS is 4.12. The thresholds are as follows: Strongly Undervalued below -5.74, Undervalued between -5.74 and -0.81, Fairly Valued between 9.05 and -0.81, Overvalued between 9.05 and 13.99, and Strongly Overvalued above 13.99. The current Forward PS of 1.40 falls within the Historic Trend Line -Fairly Valued range.

1.07

P/OCF

TherapeuticsMD Inc. (TXMD) has a current P/OCF of 1.07. The 5-year average P/OCF is -1.39. The thresholds are as follows: Strongly Undervalued below -7.63, Undervalued between -7.63 and -4.51, Fairly Valued between 1.72 and -4.51, Overvalued between 1.72 and 4.84, and Strongly Overvalued above 4.84. The current Forward P/OCF of 1.07 falls within the Historic Trend Line -Fairly Valued range.

8.57

P/FCF

TherapeuticsMD Inc. (TXMD) has a current P/FCF of 8.57. The 5-year average P/FCF is 1.06. The thresholds are as follows: Strongly Undervalued below -11.62, Undervalued between -11.62 and -5.28, Fairly Valued between 7.40 and -5.28, Overvalued between 7.40 and 13.74, and Strongly Overvalued above 13.74. The current Forward P/FCF of 8.57 falls within the Overvalued range.

TherapeuticsMD Inc (TXMD) has a current Price-to-Book (P/B) ratio of 0.45. Compared to its 3-year average P/B ratio of 0.59 , the current P/B ratio is approximately -24.30% higher. Relative to its 5-year average P/B ratio of -3.41, the current P/B ratio is about -113.20% higher. TherapeuticsMD Inc (TXMD) has a Forward Free Cash Flow (FCF) yield of approximately 6.51%. Compared to its 3-year average FCF yield of -98.84%, the current FCF yield is approximately -106.59% lower. Relative to its 5-year average FCF yield of -86.92% , the current FCF yield is about -107.50% lower.

0.45

P/B

Median3y

0.59

Median5y

-3.41

6.51

FCF Yield

Median3y

-98.84

Median5y

-86.92

Competitors Valuation Multiple

The average P/S ratio for TXMD's competitors is 9.21, providing a benchmark for relative valuation. TherapeuticsMD Inc Corp (TXMD) exhibits a P/S ratio of 1.40, which is -84.83% above the industry average. Given its robust revenue growth of 306.84%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

COSCIENS Biopharma Inc

Artelo Biosciences Inc

Loss

11.96M

MBRX.O

Moleculin Biotech Inc

Loss

11.48M

Performance Decomposition

Market capitalization of TXMD decreased by 35.37% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 234.00K to 952.00K.

The secondary factor is the Margin Expansion, contributed -112.76%to the performance.

Overall, the performance of TXMD in the past 1 year is driven by Revenue Growth. Which is more sustainable.

306.84%

234.00K → 952.00K

Revenue Growth

-112.76%

-448.72 → 57.25

Margin Expansion

-229.45%

16.39 → -21.22

P/E Change

-35.37%